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10-7 per donor cell in broth mating, respectively. Tn1546-like
elements encoding vanA-type VRE were classiﬁed into ten types,
and most of them contained both IS1216V and IS1542 insertions.
The results suggested that the disseminations of VRE were by
Tn1546-like elements being acquired by the conjugative plasmids
and transferred among E. francium strains.
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CS3-01 Cryptococcosis in AIDS Patients: From Research
to Practices in Resource-Limited Settings
Somnuek Sungkanuparph*. Division of Infectious Diseases,
Department of Medicine, Faculty of Medicine Ramathibodi
Hospital, Mahidol University, Bangkok, Thailand
Cryptococcosis is the most common life-threatening fungal infec-
tion among AIDS patients in resource-limited settings. It almost
always occurs in patients with severe immunodeﬁciency and
HIV-infected patients in resource-limited settings usually present
with advanced HIV disease. The mortality rate from cryptococ-
cosis in these settings is relatively high even with antifungal
treatment. Several randomized clinical trials have demonstrated
that primary prophylaxis with ﬂuconazole reduces the incidence
of cryptococcosis in patients with advanced HIV disease, partic-
ularly those with CD4 counts <100 cells/μL. A controlled trial in
Thailand also demonstrated a survival beneﬁt. Although primary
prophylaxis for cryptococcosis is not generally recommended in
high-income countries, it may be more beneﬁcial in resource-
limited countries because of the higher incidence of disease
and the limited capacity of diagnosis and treatment. Primary
prophylaxis with ﬂuconazole is recommended in Thailand for
years while the recent WHO guidelines for essential prevention
of opportunistic infections suggest that azole prophylaxis should
be considered for HIV-infected patients with WHO clinical stage 4
or CD4 <100 cells/μL, whether they are on antiretroviral therapy
(ART) or not. A study of antifungal susceptibilities of Cryptococ-
cus neoformans isolates has shown that the MICs of ﬂuconazole
are not higher with ﬂuconazole prophylaxis.
Treatment of choice for cryptococcosis includes combination
of amphotericin B and ﬂucytosine for 2 weeks and followed
with ﬂuconazole 400 mg/day for 8-10 weeks. However, ﬂucyto-
sine is not available in most developing countries. Prior studies
of combination of amphotericin B and ﬂuconazole had shown
controversial outcomes. A recent randomized, phase II trial in
Thailand and the United States has compared the safety and
efﬁcacy of amphotericin B with that of amphotericin B plus
low-dosed or high-dosed ﬂuconazole. There are no differences
in treatment-related toxicities among the three arms. A trend
towards better outcomes in the combination therapy arms is
seen at days 42 and 70. These results have signiﬁcant treatment
implications and should be validated in a randomized phase III
trial.
In the pre-ART era, relapses were frequent and secondary pro-
phylaxis with ﬂuconazole had been recommended for life-long.
The studies of ART initiation among patients with cryptococcosis
in resource-limited settings have shown that the incidence of new
cases and rate of relapsed disease are dramatically reduced, and
the survival has markedly increased. Prospective studies from
resource-limited settings had also demonstrated that discontin-
uation of secondary prophylaxis is safe when patients achieve
successful immune restoration from ART.
Cryptococcal immune reconstitution inﬂammatory syndrome (C-
IRIS) is characterized a clinical deterioration of cryptococcosis
following initiation of ART. Some studies report that C-IRIS is
observed more frequently in severely immunocompromised pa-
tients with disseminated infection or early ART initiation after
cryptococcosis. This may partly explain the high incidence of
C-IRIS in resource-limited settings. However, a standard case
deﬁnition of C-IRIS has not been available. The International
Network for the Study of HIV-associated IRIS has been working
for the practical case deﬁnition of C-IRIS to provide a tool for
clinical use, particularly in resource-limited settings, and future
epidemiologic studies.
CS3-02 Harnessing Multidrug Resistance Gene Expression
for Effective Antifungal Strategies by a Natural
Product Berberine
Lixin Zhang*. Institute of Microbiology, Chinese Academy of
Sciences, Beijing, China
The effectiveness of existing drugs is increasingly compromised
by the emergence of drug-resistant pathogens. Upregulating
multidrug-resistance (MDR) pumps, which confers enhanced re-
sistance to chemically unrelated alien substances, is a major
source of microbial drug resistance. A major challenge in devel-
oping efﬁcacious antibiotics against drug-resistant pathogens is
to identify compounds that could counteract MDR functions. In
the human pathogen Candida albicans, Mdr1p plays a key role in
azole-resistant clinical isolates.
Here we report an unexpected consequence of MDR1 upreg-
ulation: it confers enhanced sensitivity to a natural product,
berberine. This effect of MDR1 overexpression is at least in part
due to enhanced accumulation of berberine inside cells. In sup-
port of this notion, a number of berberine structural analogues
exhibited a similar MDR1-dependent antifungal activity. We also
show that berberine is indeed highly efﬁcacious in inhibiting
the growth of azole-resistant clinical C. albicans isolates with
upregulated MDR1 from HIV infected patients. Our study reveals
a novel function of MDR1 in raising sensitivity of drug-resistant
fungal pathogens to selected natural products. Thus, the drug
resistance phenotype conferred by MDR1 overexpression could be
harnessed through the use of MDR1-dependent cytotoxic agents,
such as berberine, for effective antifungal strategies.
CS3-03 Combination Antifungals – Is There a Role?
B.H. Tan*. Department of Internal Medicine, Singapore General
Hospital, Singapore
Traditionally, antibiotics have been combined to treat polymicro-
bial infections, in initial therapy, and to prevent the emergence
of resistance. For years, the hope has been that combining anti-
fungals would produce the same effects. In medical mycology,
however, very few combinations have made it to standard recom-
mendations. The combination of amphotericin B and ﬂucytosine
in the initial treatment of cryptococcal meningitis is a case in
point. That combining antifungals is not yet quite standard prac-
tice stems from problems in interpreting the literature. The same
combination of drugs have produced different results in different
laboratories! This likely has to do with the fact that most of the
tests are not standardized. Further, the best clinical data come
only from retrospective studies. In this talk the literature on
combinatino antifungals will be reviewed.
CS3-04 The Echinocandins and Formulary Decision
Mamie Hui *. Department of Microbiology, the Chinese University
of Hong Kong, Hong Kong, China
Invasive fungal infections have always been a difﬁcult to treat
infectious diseases with high mortality. This is due to the im-
munocompromised state of the patients as well as toxicities
of antifungal treatments. Traditionally, only the azoles and the
polyenes are available for treatment of these patients. Recently,
a novel class of antifungal agents, the echinocandins, have
emerged with promising safety proﬁles. These agents act by
inhibiting the synthesis of 1,3-β-D-glucan of fungal cell wall.
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They are effective in the treatment of candidaemia, esophaegeal
candidaisis, and aspergillus infections. Selected agents can also
be used for prophylaxis in stem cell transplant recipients and
other candida infections. Currently, there are 3 echinocandins
available, caspofungin, micafungin and anidulafungin. No dosage
adjustment is required for renal impairment. Only caspofun-
gin requires adjustment in liver insufﬁciency. Pharmacokinetic-
pharmacodynamic studies have identiﬁed that these agents are
concentration dependent with post-antifungal effect. Therefore
a single daily dosing regimen is usually sufﬁcient. In addition,
novel dosing regimen such as extended interval dosing (alternate
day or even weekly) may be possible as demonstrated in animal
models. While these agents have demonstrated similar efﬁcacy,
patients’ comfort would be another considerations in the choice
of anti-infective agents. Possibility on extended interval dosing,
and drug cost would impact on the hospital decision on their
formulary placement.
Concurrent Session 4 – HCV Development and
Strategies
CS4-01 Response-guided Therapy for Chronic Hepatitis C
Stefan Zeuzem*. Professor of Medicine, Chief, Department of
Medicine, Goethe University Hospital, Frankfurt a.M., Germany
Pegylated interferon alfa in combination with ribavirin admin-
istered for 48 and 24 weeks has been approved as standard
antiviral treatment in patients with HCV genotype 1 (4-6) and
2/3 infection, respectively, in many countries. Different virus-
and host-related baseline parameters are known to predict
the probability of sustained virologic response including HCV
genotype, HCV viral load, gamma glutamyltranspeptidase (GGT)
levels, age and liver ﬁbrosis. While HCV genotype 2, 3 infected
patients are generally treated for 24 weeks, management of
therapy is based on early discontinuation rules in HCV genotype
1 infected patients with a low or no chance of further sustained
virologic response. Thereby, a decline of less than 2 log10 steps
at week 12 in comparison with baseline (early virologic response,
EVR) and detectable HCV RNA at week 24 by a sensitive assay
(detection limit ≤50 IU/ml) can be safely used as stopping rules
with predictive values of 98-100% for virologic non-response. Fu-
ture developments are aiming for individualization of treatment
duration based on HCV RNA concentrations before initiation
of therapy and decline early during therapy. Rapid virologic
response (RVR) deﬁned as undetectable HCV RNA at week 4
of therapy (≤50 IU/ml) together with low baseline viral load
(≤600.000 IU/ml) were introduced as parameters for shortening
of treatment duration in HCV genotype 1 infected patients with-
out a loss of the probability of sustained virologic response. Vice
versa in patients with a slow virologic response which become
HCV RNA negative at the ﬁrst time at week 24 of therapy prolon-
gation of treatment duration to 72 weeks seems to be associated
with increased sustained virologic response rates. Similar in HCV
genotype 2, 3 infected patients reduction of treatment duration
from 24 to 12-16 weeks was investigated in different clinical
trials. However, in several studies shortening therapy to 12-16
weeks higher relapse rates were reported and future trials are
needed to deﬁne subgroups of patients with speciﬁc baseline
parameters (e.g. genotype, viral load, degree of ﬁbrosis) and
RVR at week 4 for a safe reduction of treatment duration.
Basic to the development of new speciﬁc anti-HCV drugs is the
understanding of the viral life cycle, in particular the genomic or-
ganization and the polyprotein processing. Major progress in this
ﬁeld was achieved due to the development of sub-genomic and
more recently full-genomic replicon systems. The HCV genome
is a single-stranded RNA molecule that contains a single open
reading frame encoding a polyprotein of about 3000 amino acids.
The polyprotein is subsequently processed at the level of the
endoplasmic reticulum (ER) by cellular and viral proteases to
yield 4 structural and 6 non-structural proteins. The open read-
ing frame is ﬂanked by 5’ and 3’ untranslated regions. Each
single HCV structure represents a potential antiviral target. An-
tisense oligonucleotides, ribozymes, siRNA, and small molecules
have been targeted in particular against the 5’-noncoding region
with substantial success in vitro but not yet in vivo. Inhibition
of nucleocapsid formation to the icosahedral viral coat is an
attractive target, however, no speciﬁc molecules have yet been
developed. Envelope proteins HCV E1 and E2 are the basis for the
development of prophylactic and/or therapeutic vaccines.
NS3 and NS4A are cleaved by the catalytic activity of the NS3
protease domain. In addition to the protease domain located in
the 189 aminoterminal amino acids, NS3 also possesses a helicase
domain located in the 442 carboxyterminal amino acids. The
NS3 protease domain is responsible to complete the polyprotein
processing down to NS4B, NS5A, and NS5B. Despite the fact that
the catalytic site is a shallow and largely hydrophobic groove and
therefore very difﬁcult to target several compounds have been
successfully designed (BILN 2061, VX-950, SCH503034, etc.). The
NS5B RNA-dependent RNA polymerase is the key enzyme for syn-
thesis of a complementary minus-strand RNA using the genome as
template, and the subsequent synthesis of genomic plus-strand
RNA from this minus-strand RNA template. The active site of
the enzyme is a target for nucleoside/nucleotide analogue in-
hibitors. Nonnucleoside inhibitors, reported to bind at various
sites, may act by blocking the enzyme in the initiation mode
through inhibition of a conformational change needed to proceed
with elongation.
CS4-02 Treatment of Different Genotypes in Chronic
Hepatitis C
James Y.Y. Fung*. Department of Medicine, University of Hong
Kong, Hong Kong
Hepatitis C virus (HCV) affects an estimated 175 million people
worldwide. Up to 4 million people will be newly infected each
year, and the majority of these will progress to chronic infec-
tion. There are currently six major genotypes, with geographical
differences in the distribution of these different genotypes. In
China, the predominant genotypes are 1b and 2a, compared to
Hong Kong, where the predominant genotypes are 1b and 6.
The most important clinical implication of HCV genotypes lies
in the differences in response to antiviral therapy between the
different genotypes, and HCV genotypes is the strongest pre-
dictor of treatment response. Therefore, the determination of
HCV genotype has become an essential part in the treatment of
chronic hepatitis C. The exact mechanism of why some geno-
types are more difﬁcult to treat than others remains unknown,
and is likely to involve both host and viral factors. With our
current knowledge, patients infected with genotype 1 and 4 have
an inferior response to interferon-based therapy compared to
patients with genotypes 2, 3, 5 and 6.
CS4-03 Mechanism of IFN-gamma in Anti-HCV Infection
Xuefan Bai *. Department of Infectious Diseases, Tangdu
Hospital, Fourth Military Medical University, Xi’an, China
CS4-04 The Impact of Lipid Proﬁles on HCV RNA Levels in
Patients with Genotypes 1 and 2
Chen-Hua Liu*. Department of Internal Medicine, National
Taiwan University Hospital, Taipei, Taiwan
Chronic hepatitis C virus (HCV) infection, a leading cause of cir-
rhosis, hepatocellular carcinoma (HCC) and liver failure, affects
more than 170 million people worldwide. Despite the improving
